{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T18:03:22Z","timestamp":1790964202053,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2007,4,1]],"date-time":"2007-04-01T00:00:00Z","timestamp":1175385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2007,4]]},"DOI":"10.1016\/j.clinthera.2007.03.015","type":"journal-article","created":{"date-parts":[[2007,7,6]],"date-time":"2007-07-06T11:20:34Z","timestamp":1183720834000},"page":"602-610","source":"Crossref","is-referenced-by-count":22,"title":["Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: A sequential, randomized, double-blind clinical trial"],"prefix":"10.1016","volume":"29","author":[{"given":"Giuseppe","family":"Derosa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arrigo F.G.","family":"Cicero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"D'Angelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Fogari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibilla","family":"Salvadeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Gravina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Fassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Fogari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2007.03.015_bib1","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/01.hjh.0000165622.34192.fd","article-title":"Lowering blood pressure for cardiovascular risk reduction","volume":"23","author":"McInnes","year":"2005","journal-title":"J Hypertens Suppl"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2007.03.015_bib2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1524-6175.2006.05379.x","article-title":"Hypertensiona treatable component of the cardiometabolic syndrome: Challenges for the primary care physician","volume":"8","author":"Manrique","year":"2006","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.clinthera.2007.03.015_bib3","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1097\/00001573-199309000-00006","article-title":"Epidemiologic, physiologic, and clinical implications of hypertension and insulin resistance","volume":"8","author":"O'Shaughnessy","year":"1993","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.clinthera.2007.03.015_bib4","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.2337\/diacare.27.6.1496","article-title":"Lipids and lipoproteins in patients with type 2 diabetes","volume":"27","author":"Krauss","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2007.03.015_bib5","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.2337\/diacare.26.4.1251","article-title":"Carotid atherosclerosis and coronary heart disease in the metabolic syndrome: Prospective data from the Bruneck study","volume":"26","author":"Bonora","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2007.03.015_bib6","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Knowler","year":"2002","journal-title":"N Eng J Med"},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2007.03.015_bib7","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1038\/sj.ijo.0802125","article-title":"Pathways from obesity to hypertension: From the perspective of a vicious triangle","volume":"26","author":"Montani","year":"2002","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1016\/j.clinthera.2007.03.015_bib8","first-page":"411","article-title":"Contribution of sympathetic nervous system overactivity to cardiovascular and metabolic disease","volume":"9","author":"Ernsberger","year":"1998","journal-title":"Rev Contemp Pharmacother"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2007.03.015_bib9","first-page":"21","article-title":"Screening for diabetes (Position Statement)","volume":"24","author":"American Diabetes Association","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2007.03.015_bib10","first-page":"151","article-title":"1999 World Health OrganizationInternational Society of Hypertension Guidelines for the Management of Hypertension","volume":"17","author":"Guidelines Subcommittee","year":"1999","journal-title":"J Hypertens"},{"key":"10.1016\/j.clinthera.2007.03.015_bib11","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S0140-6736(95)91747-0","article-title":"Prevention of diabetic renal disease with special reference to microalbuminuria","volume":"346","author":"Mogensen","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2007.03.015_bib12","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.0954-6820.1959.tb10400.x","article-title":"Vibratory perception in diabetics during arrested blood flow to the limb","volume":"163","author":"Steiness","year":"1959","journal-title":"Acta Med Scand"},{"key":"10.1016\/j.clinthera.2007.03.015_bib13","series-title":"International Ethical Guidelines for Biomedical Research Involving Human Subjects","year":"1993"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2007.03.015_bib14","first-page":"S44","article-title":"Nutrition recommendations and principles for people with diabetes mellitus (Position Statement)","volume":"24","author":"American Diabetes Association","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2007.03.015_bib15","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1046\/j.1464-5491.1999.00166.x","article-title":"A desktop guide to Type 2 diabetes mellitus","volume":"16","author":"European Diabetes Policy Group 1999","year":"1999","journal-title":"Diabet Med"},{"key":"10.1016\/j.clinthera.2007.03.015_bib16","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/BF01225569","article-title":"Determination of total serum insulin (IRI) in insulin-treated diabetic patients","volume":"8","author":"Heding","year":"1972","journal-title":"Diabetologia"},{"key":"10.1016\/j.clinthera.2007.03.015_bib17","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1126\/science.635569","article-title":"The glycosylation of hemoglobin: Relevance to diabetes mellitus","volume":"200","author":"Bunn","year":"1978","journal-title":"Science"},{"key":"10.1016\/j.clinthera.2007.03.015_bib18","first-page":"121","article-title":"Enzymatic determination of total cholesterol with the Greiner Selective Analyzer (GSA II)","volume":"15","author":"Borner","year":"1978","journal-title":"J Clin Chem Clin Biochem"},{"key":"10.1016\/j.clinthera.2007.03.015_bib19","series-title":"Methods of Enzymatic Analysis","first-page":"18","article-title":"Triglycerides: Determination after enzymatic hydrolysis","author":"Wahlefeld","year":"1974"},{"key":"10.1016\/j.clinthera.2007.03.015_bib20","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1172\/JCI103182","article-title":"The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum","volume":"34","author":"Havel","year":"1955","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clinthera.2007.03.015_bib21","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin Chem"},{"key":"10.1016\/j.clinthera.2007.03.015_bib22","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"10.1016\/j.clinthera.2007.03.015_bib23","series-title":"Statistical Principles in Experimental Design","author":"Winer","year":"1971"},{"issue":"Suppl 4","key":"10.1016\/j.clinthera.2007.03.015_bib24","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1097\/00005344-200000004-00007","article-title":"Moxonidine: A new and versatile anti hypertensive","volume":"35","author":"Messerli","year":"2000","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.clinthera.2007.03.015_bib25","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1046\/j.1463-1326.1999.00042.x","article-title":"Metabolic effects of moxonidine and other centrally acting anti hypertensives","volume":"1","author":"Schachter","year":"1999","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2007.03.015_bib26","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0022-3565(24)37935-2","article-title":"Mechanisms of anti hyperglycemic effects of moxonidine in the obese spontaneously hypertensive Koletsky rat (SHROB)","volume":"288","author":"Ernsberger","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.clinthera.2007.03.015_bib27","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.2337\/diabetes.48.5.1093","article-title":"Metabolic and hemodynamic effects of mox onidine in the Zucker diabetic fatty rat model of type 2 diabetes","volume":"48","author":"Yakubu-Madus","year":"1999","journal-title":"Diabetes"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2007.03.015_bib28","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/BF00120497","article-title":"Sympathetic nervous system in salt-sensitive and obese hypertension: Amelioration of multiple abnormalities by a central sympatholytic agent","volume":"10","author":"Ernsberger","year":"1996","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.clinthera.2007.03.015_bib29","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1161\/01.HYP.30.6.1560","article-title":"Anti hypertensive agent moxonidine enhances muscle glucose trans port in insulin-resistant rats","volume":"30","author":"Henriksen","year":"1997","journal-title":"Hypertension"},{"key":"10.1016\/j.clinthera.2007.03.015_bib30","first-page":"S29","article-title":"Moxonidine improves insulin sensitivity in insulinresistant hypertensives","volume":"17","author":"Haenni","year":"1999","journal-title":"J Hypertens Suppl"},{"key":"10.1016\/j.clinthera.2007.03.015_bib31","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.1368-5031.2004.00158.x","article-title":"Effect of moxonidine on lipid subfractions in patients with hypertension","volume":"58","author":"Lumb","year":"2004","journal-title":"Int J Clin Pract"},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2007.03.015_bib32","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1097\/00004872-200006001-00022","article-title":"Insulin resistance and arterial hypertension. The influence of moxonidine and metformin therapy","volume":"18","author":"Almazov","year":"2000","journal-title":"J Hypertens"},{"key":"10.1016\/j.clinthera.2007.03.015_bib33","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1463-1326.2006.00606.x","article-title":"Moxonidine improves glycaemic control in mildly hypertensive, over weight patients: A comparison with metformin","volume":"8","author":"Chazova","year":"2006","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2007.03.015_bib34","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1161\/01.CIR.0000127955.36250.65","article-title":"Angiotensin type 1 receptor blockers induce peroxisome proliferator activated receptor-gamma activity","volume":"109","author":"Schupp","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2007.03.015_bib35","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/01.fjc.0000161403.91456.39","article-title":"Effects of doxazosin and irbesartan on blood pressure and metabolic control in patients with type 2 diabetes and hypertension","volume":"45","author":"Derosa","year":"2005","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.clinthera.2007.03.015_bib36","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive sum mary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)","volume":"285","author":"Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults","year":"2001","journal-title":"JAMA"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2007.03.015_bib37","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.2337\/diacare.29.s1.06.s4","article-title":"Standards of medical care in diabetes 2006","volume":"29","author":"American Diabetes Association","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2007.03.015_bib38","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/sj.jhh.1001683","article-title":"Guidelines for management of hypertension: Report of the Fourth Working Party of the British Hypertension Society, 2004-BHS IV","volume":"18","author":"Williams","year":"2004","journal-title":"J Hum Hypertens"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291807000847?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291807000847?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T07:22:23Z","timestamp":1737184943000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291807000847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["S0149291807000847"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2007.03.015","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2007,4]]}}}